Asahi Kasei Medical Completes Acquisition of Bionova Scientific, U.S.-based biopharmaceutical CDMO | 2022 | News | Asahi Kasei
  • Press Releases

Asahi Kasei Medical Completes Acquisition of Bionova Scientific, U.S.-based biopharmaceutical CDMO

June 1, 2022
Asahi Kasei Medical Co., Ltd.

Asahi Kasei Medical has completed its acquisition of Bionova Scientific, LLC, a provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies as announced on April 19, 2022. The acquisition closed on May 31, 2022 (US Pacific time).

Bionova Scientific will operate as a business unit within Asahi Kasei Medical’s Bioprocess Division, and Darren Head, the current CEO of Bionova Scientific, will continue to lead the company. Bionova Scientific will continue to expand its business by building on its strengths as a CDMO specialized in the process design and manufacture of various types of biologics that are particularly difficult to develop. Moving forward, Asahi Kasei Medical aims to provide biopharmaceutical companies with further added value and higher customer satisfaction by leveraging its existing bioprocess consumables, equipment and biosafety testing services businesses together with Bionova Scientific’s biologics CDMO business.

For reference: